Breaking News

Today
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Regeneron reports Q2 EYLEA U.S. net sales $1.11B vs. $1.16B last year » 06:55
08/05/20
08/05
06:55
08/05/20
06:55
REGN

Regeneron

$647.09 /

+1.76 (+0.27%)

, SNY

Sanofi

$51.79 /

-1.42 (-2.67%)

, BAYRY

Bayer

$0.00 /

+ (+0.00%)

Regeneron (REGN) said in…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
SNY Sanofi
$51.79 /

-1.42 (-2.67%)

REGN Regeneron
$647.09 /

+1.76 (+0.27%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

REGN Regeneron
$647.09 /

+1.76 (+0.27%)

08/04/20 Morgan Stanley
Regeneron preclinical antibody cocktail data 'encouraging,' says Morgan Stanley
07/20/20 Credit Suisse
Regeneron price target raised to $716 from $700 at Credit Suisse
07/09/20
Fly Intel: Top five analyst upgrades
07/08/20 Truist
Regeneron upgraded to Buy at SunTrust on Eylea resilience and pipeline
SNY Sanofi
$51.79 /

-1.42 (-2.67%)

07/31/20 JPMorgan
Sanofi price target raised to EUR 106 from EUR 103 at JPMorgan
07/20/20 BMO Capital
Immunic initiated with an Outperform at BMO Capital
07/08/20 Piper Sandler
Piper upgrades Kiadis on 'platform validating' Sanofi deal
07/06/20 Citi
BioMarin price target raised to $148 from $105 at Citi
BAYRY Bayer
$0.00 /

+ (+0.00%)

06/26/20 JPMorgan
Bayer price target raised to EUR 77 from EUR 75 at JPMorgan
06/26/20 Deutsche Bank
Bayer price target raised to EUR 87 from EUR 85 at Deutsche Bank
06/25/20 Morgan Stanley
Bayer price target raised to EUR 88 from EUR 83 at Morgan Stanley
06/25/20 HSBC
HSBC upgrades Bayer to Buy after settlement on most Monsanto cases in U.S.
SNY Sanofi
$51.79 /

-1.42 (-2.67%)

REGN Regeneron
$647.09 /

+1.76 (+0.27%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

  • 27
    May
SNY Sanofi
$51.79 /

-1.42 (-2.67%)

REGN Regeneron
$647.09 /

+1.76 (+0.27%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

SNY Sanofi
$51.79 /

-1.42 (-2.67%)

REGN Regeneron
$647.09 /

+1.76 (+0.27%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

SNY Sanofi
$51.79 /

-1.42 (-2.67%)

REGN Regeneron
$647.09 /

+1.76 (+0.27%)

Yesterday
Hot Stocks
Ideaya Biosciences announces HSR clearance of GlaxoSmithKline partnership » 06:14
08/04/20
08/04
06:14
08/04/20
06:14
IDYA

Ideaya Biosciences

$11.50 /

-1.09 (-8.66%)

, GSK

GlaxoSmithKline

$41.28 /

+0.975 (+2.42%)

Ideaya Biosciences…

Ideaya Biosciences announced the effectiveness of the collaboration, option and license agreement between the company and GlaxoSmithKline (GSK) following clearance under the Hart-Scott-Rodino Antitrust Improvements Act, or HSR. Pursuant to the agreement, Ideaya received an upfront cash payment of $100M from GSK. The strategic partnership in Synthetic Lethality includes Ideaya's MAT2A, Pol Theta, and Werner Helicase programs. Ideaya also announced closing of a direct private placement equity financing pursuant to a stock purchase agreement between Ideaya and Glaxo Group. Glaxo Group purchased 1,333,333 shares of Ideaya's common stock at a price per share of $15.00. Ideaya received proceeds from Glaxo Group of approximately $20M. Ideaya expects current cash, cash equivalents and marketable securities to support planned operations into 2024.

ShowHide Related Items >><<
IDYA Ideaya Biosciences
$11.50 /

-1.09 (-8.66%)

GSK GlaxoSmithKline
$41.28 /

+0.975 (+2.42%)

IDYA Ideaya Biosciences
$11.50 /

-1.09 (-8.66%)

07/30/20 Roth Capital
Roth Capital bullish on Ideaya as GSK highlights synthetic lethality pipeline
07/13/20 JPMorgan
Ideaya upgraded to Overweight on recent pullback at JPMorgan
07/13/20 JPMorgan
Ideaya Biosciences upgraded to Overweight from Neutral at JPMorgan
06/17/20 H.C. Wainwright
Ideaya Biosciences price target raised to $22 from $13 at H.C. Wainwright
GSK GlaxoSmithKline
$41.28 /

+0.975 (+2.42%)

07/31/20 Barclays
Barclays backs Underweight on GSK after 'challenging' Q2
07/13/20 UBS
UBS reiterates Buy on GSK as FDA belantamab docs are out
IDYA Ideaya Biosciences
$11.50 /

-1.09 (-8.66%)

GSK GlaxoSmithKline
$41.28 /

+0.975 (+2.42%)

  • 18
    Jun
GSK GlaxoSmithKline
$41.28 /

+0.975 (+2.42%)

IDYA Ideaya Biosciences
$11.50 /

-1.09 (-8.66%)

GSK GlaxoSmithKline
$41.28 /

+0.975 (+2.42%)

IDYA Ideaya Biosciences
$11.50 /

-1.09 (-8.66%)

GSK GlaxoSmithKline
$41.28 /

+0.975 (+2.42%)

Monday
Options
Unusually active option classes on open August 3rd » 09:40
08/03/20
08/03
09:40
08/03/20
09:40
EWJ

iShares MSCI Japan Index Fund

$54.34 /

+ (+0.00%)

, MOS

Mosaic

$13.48 /

+ (+0.00%)

, CLX

Clorox

$236.20 /

+ (+0.00%)

, GSK

GlaxoSmithKline

$40.31 /

+ (+0.00%)

, VALE

Vale

$11.63 /

+ (+0.00%)

, MSFT

Microsoft

$205.00 /

+ (+0.00%)

, RIOT

Riot Blockchain

$2.62 /

+ (+0.00%)

, UNG

United States Natural Gas Fund

$10.27 /

+ (+0.00%)

, JMIA

Jumia Technologies

$15.51 /

+ (+0.00%)

, MPC

Marathon Petroleum

$38.24 /

+ (+0.00%)

Unusual total active…

Unusual total active option classes on open include: iShares Japan (EWJ), Mosaic (MOS), Clorox (CLX), GlaxoSmithKline (GSK), Vale (VALE), Microsoft (MSFT), Riot Blockchain (RIOT), U.S. Natural Gas Fund (UNG), Jumia Technologies (JMIA), and Marathon Petroleum (MPC).

ShowHide Related Items >><<
VALE Vale
$11.63 /

+ (+0.00%)

RIOT Riot Blockchain
$2.62 /

+ (+0.00%)

MSFT Microsoft
$205.00 /

+ (+0.00%)

MPC Marathon Petroleum
$38.24 /

+ (+0.00%)

MOS Mosaic
$13.48 /

+ (+0.00%)

JMIA Jumia Technologies
$15.51 /

+ (+0.00%)

GSK GlaxoSmithKline
$40.31 /

+ (+0.00%)

CLX Clorox
$236.20 /

+ (+0.00%)

EWJ iShares MSCI Japan Index Fund
$54.34 /

+ (+0.00%)

MOS Mosaic
$13.48 /

+ (+0.00%)

07/15/20 Citi
Mosaic upgraded to Buy from Neutral at Citi
06/29/20
Fly Intel: Top five analyst upgrades
06/29/20 BofA
Mosaic upgraded to Buy from Underperform at BofA
05/11/20 BofA
Nutrien, Mosaic, Corteva, CF Industries cut to Underperform at BofA
CLX Clorox
$236.20 /

+ (+0.00%)

07/27/20 Deutsche Bank
Clorox price target raised to $223 from $174 at Deutsche Bank
07/16/20 JPMorgan
Clorox price target raised to $235 from $203 at JPMorgan
06/30/20 DA Davidson
Clorox initiated with a Buy at DA Davidson
06/29/20 DA Davidson
Clorox initiated with a Buy at DA Davidson
GSK GlaxoSmithKline
$40.31 /

+ (+0.00%)

07/31/20 Barclays
Barclays backs Underweight on GSK after 'challenging' Q2
07/30/20 Roth Capital
Roth Capital bullish on Ideaya as GSK highlights synthetic lethality pipeline
07/13/20 UBS
UBS reiterates Buy on GSK as FDA belantamab docs are out
07/13/20 JPMorgan
Ideaya upgraded to Overweight on recent pullback at JPMorgan
VALE Vale
$11.63 /

+ (+0.00%)

06/11/20 Deutsche Bank
Vale price target raised to $13 from $11 at Deutsche Bank
06/09/20 GLJ Research
Fortescue Metals upgraded to Hold from Sell at GLJ Research
06/05/20 Exane BNP Paribas
Vale upgraded to Outperform from Neutral at Exane BNP Paribas
06/03/20 UBS
Vale upgraded to Buy from Neutral at UBS
MSFT Microsoft
$205.00 /

+ (+0.00%)

08/03/20 Wedbush
Wedbush sees a TikTok deal as big bet from Microsoft on social media space
07/31/20 Stifel
Citrix disclosure points to $1B commitment, most likely to Azure, says Stifel
07/27/20 Morgan Stanley
Morgan Stanley downgrades Software industry view to In-Line from Attractive
07/23/20
Fly Intel: Top five analyst downgrades
RIOT Riot Blockchain
$2.62 /

+ (+0.00%)

UNG United States Natural Gas Fund
$10.27 /

+ (+0.00%)

JMIA Jumia Technologies
$15.51 /

+ (+0.00%)

05/14/20 Stifel
Jumia Technologies downgraded to Hold from Buy at Stifel
03/25/20 Berenberg
Jumia Technologies downgraded to Hold from Buy at Berenberg
02/26/20 RBC Capital
Jumia Technologies price target lowered to $13 from $22 at RBC Capital
02/25/20 Stifel
Jumia Technologies price target lowered to $8 from $10 at Stifel
MPC Marathon Petroleum
$38.24 /

+ (+0.00%)

08/03/20 Morgan Stanley
Marathon sale of Speedway for $21B a 'positive outcome,' says Morgan Stanley
07/15/20 Morgan Stanley
MPLX downgraded to Equal Weight from Overweight at Morgan Stanley
05/13/20 Morgan Stanley
U.S. gasoline consumption appears to have bottomed, says Morgan Stanley
04/24/20 Citi
Marathon Petroleum downgraded to Neutral from Buy at Citi
VALE Vale
$11.63 /

+ (+0.00%)

MSFT Microsoft
$205.00 /

+ (+0.00%)

MPC Marathon Petroleum
$38.24 /

+ (+0.00%)

MOS Mosaic
$13.48 /

+ (+0.00%)

GSK GlaxoSmithKline
$40.31 /

+ (+0.00%)

CLX Clorox
$236.20 /

+ (+0.00%)

VALE Vale
$11.63 /

+ (+0.00%)

MSFT Microsoft
$205.00 /

+ (+0.00%)

MPC Marathon Petroleum
$38.24 /

+ (+0.00%)

GSK GlaxoSmithKline
$40.31 /

+ (+0.00%)

CLX Clorox
$236.20 /

+ (+0.00%)

VALE Vale
$11.63 /

+ (+0.00%)

RIOT Riot Blockchain
$2.62 /

+ (+0.00%)

MSFT Microsoft
$205.00 /

+ (+0.00%)

MPC Marathon Petroleum
$38.24 /

+ (+0.00%)

MOS Mosaic
$13.48 /

+ (+0.00%)

JMIA Jumia Technologies
$15.51 /

+ (+0.00%)

GSK GlaxoSmithKline
$40.31 /

+ (+0.00%)

CLX Clorox
$236.20 /

+ (+0.00%)

VALE Vale
$11.63 /

+ (+0.00%)

UNG United States Natural Gas Fund
$10.27 /

+ (+0.00%)

RIOT Riot Blockchain
$2.62 /

+ (+0.00%)

MSFT Microsoft
$205.00 /

+ (+0.00%)

MPC Marathon Petroleum
$38.24 /

+ (+0.00%)

MOS Mosaic
$13.48 /

+ (+0.00%)

JMIA Jumia Technologies
$15.51 /

+ (+0.00%)

GSK GlaxoSmithKline
$40.31 /

+ (+0.00%)

EWJ iShares MSCI Japan Index Fund
$54.34 /

+ (+0.00%)

CLX Clorox
$236.20 /

+ (+0.00%)

MSFT Microsoft
$205.00 /

+ (+0.00%)

EWJ iShares MSCI Japan Index Fund
$54.34 /

+ (+0.00%)

Saturday
On The Fly
Week in review: How Trump's policies moved stocks » 09:06
08/01/20
08/01
09:06
08/01/20
09:06
MSFT

Microsoft

$205.00 /

+1.135 (+0.56%)

, PFE

Pfizer

$38.48 /

-0.27 (-0.70%)

, AZN

AstraZeneca

$55.77 /

-2.13 (-3.68%)

, BMY

Bristol-Myers

$58.66 /

-0.22 (-0.37%)

, LLY

Eli Lilly

$150.24 /

-2.71 (-1.77%)

, GSK

GlaxoSmithKline

$40.31 /

+0.045 (+0.11%)

, JNJ

Johnson & Johnson

$145.78 /

-1.09 (-0.74%)

, MRK

Merck

$80.26 /

+1.21 (+1.53%)

, NVS

Novartis

$82.09 /

-2.115 (-2.51%)

, SNY

Sanofi

$52.43 /

-0.1 (-0.19%)

, MRNA

Moderna

$74.10 /

-3.5 (-4.51%)

, SNAP

Snap

$22.41 /

+ (+0.00%)

, TWTR

Twitter

$36.39 /

-0.34 (-0.93%)

, FB

Facebook

$253.82 /

+19.19 (+8.18%)

, GOOG

Alphabet

$1,482.46 /

-52.125 (-3.40%)

, GOOGL

Alphabet Class A

$1,487.69 /

-48.81 (-3.18%)

, AMZN

Amazon.com

$3,165.00 /

+114.03 (+3.74%)

, AAPL

Apple

$425.02 /

+39.88 (+10.35%)

, KODK

Eastman Kodak

$22.30 /

-7.53 (-25.24%)

, RHHBY

Roche

$0.00 /

+ (+0.00%)

Catch up on the top…

Open Full Text

ShowHide Related Items >><<
TWTR Twitter
$36.39 /

-0.34 (-0.93%)

SNY Sanofi
$52.43 /

-0.1 (-0.19%)

SNAP Snap
$22.41 /

+ (+0.00%)

RHHBY Roche
$0.00 /

+ (+0.00%)

PFE Pfizer
$38.48 /

-0.27 (-0.70%)

NVS Novartis
$82.09 /

-2.115 (-2.51%)

MSFT Microsoft
$205.00 /

+1.135 (+0.56%)

MRNA Moderna
$74.10 /

-3.5 (-4.51%)

MRK Merck
$80.26 /

+1.21 (+1.53%)

LLY Eli Lilly
$150.24 /

-2.71 (-1.77%)

KODK Eastman Kodak
$22.30 /

-7.53 (-25.24%)

JNJ Johnson & Johnson
$145.78 /

-1.09 (-0.74%)

GSK GlaxoSmithKline
$40.31 /

+0.045 (+0.11%)

GOOGL Alphabet Class A
$1,487.69 /

-48.81 (-3.18%)

GOOG Alphabet
$1,482.46 /

-52.125 (-3.40%)

FB Facebook
$253.82 /

+19.19 (+8.18%)

BMY Bristol-Myers
$58.66 /

-0.22 (-0.37%)

AZN AstraZeneca
$55.77 /

-2.13 (-3.68%)

AMZN Amazon.com
$3,165.00 /

+114.03 (+3.74%)

AAPL Apple
$425.02 /

+39.88 (+10.35%)

MSFT Microsoft
$205.00 /

+1.135 (+0.56%)

07/31/20 Stifel
Citrix disclosure points to $1B commitment, most likely to Azure, says Stifel
07/27/20 Morgan Stanley
Morgan Stanley downgrades Software industry view to In-Line from Attractive
07/23/20
Fly Intel: Top five analyst downgrades
07/23/20 Wedbush
Microsoft remains top cloud name at Wedbush
PFE Pfizer
$38.48 /

-0.27 (-0.70%)

07/30/20 BofA
BofA says hard to compare Moderna COVID data to competing preclinical data
07/30/20 Morgan Stanley
Pfizer price target raised to $42 from $36 at Morgan Stanley
07/30/20 Mizuho
Pfizer price target raised to $43 from $38 at Mizuho
07/28/20 SVB Leerink
Solid Biosciences downgraded to Market Perform at SVB Leerink
AZN AstraZeneca
$55.77 /

-2.13 (-3.68%)

07/31/20 Barclays
Barclays backs Overweight on AstraZeneca after Q2 results
07/29/20 Barclays
AstraZeneca price target raised to 9,300 GBp from 9,200 GBp at Barclays
07/20/20 Jefferies
AstraZeneca slide 'overdone' after 'encouraging' vaccine data, says Jefferies
BMY Bristol-Myers
$58.66 /

-0.22 (-0.37%)

07/28/20 Mizuho
Wait for Bristol-Myers' bb2121 submission making some 'nervous,' says Mizuho
07/28/20
Fly Intel: Top five analyst initiations
07/28/20 Raymond James
Bristol-Myers initiated with an Outperform at Raymond James
07/22/20 Morgan Stanley
Morgan Stanley sees 'encouraging news' coming in near-term for Bristol-Myers
LLY Eli Lilly
$150.24 /

-2.71 (-1.77%)

07/31/20 Barclays
Eli Lilly earnings selloff 'meaningful over-reaction,' says Barclays
07/15/20 H.C. Wainwright
Blueprint Medicines price target raised to $110 from $66 at H.C. Wainwright
07/14/20 Baird
Blueprint Medicines price target raised to $100 from $90 at Baird
07/14/20 Raymond James
Blueprint Medicines price target raised to $106 from $95 at Raymond James
GSK GlaxoSmithKline
$40.31 /

+0.045 (+0.11%)

07/31/20 Barclays
Barclays backs Underweight on GSK after 'challenging' Q2
07/30/20 Roth Capital
Roth Capital bullish on Ideaya as GSK highlights synthetic lethality pipeline
07/13/20 UBS
UBS reiterates Buy on GSK as FDA belantamab docs are out
07/13/20 JPMorgan
Ideaya upgraded to Overweight on recent pullback at JPMorgan
JNJ Johnson & Johnson
$145.78 /

-1.09 (-0.74%)

07/29/20 Laidlaw
Curis initiated with a Buy at Laidlaw
07/17/20 Goldman Sachs
J&J valuation discount to S&P 500 'too wide,' says Goldman Sachs
07/17/20 Citi
Johnson & Johnson price target raised to $170 from $165 at Citi
MRK Merck
$80.26 /

+1.21 (+1.53%)

07/27/20 H.C. Wainwright
Agreement termination 'optimal' for Vyleesi future, says H.C. Wainwright
06/30/20 SVB Leerink
Seattle Genetics price target raised to $167 from $155 at SVB Leerink
06/30/20 Oppenheimer
Seattle Genetics price target raised to $210 from $200 at Oppenheimer
NVS Novartis
$82.09 /

-2.115 (-2.51%)

07/28/20 Morgan Stanley
Novartis price target raised to CHF 93 from CHF 91 at Morgan Stanley
07/01/20 Piper Sandler
Amgen appeal rules in favor of patent validity, says Piper Sandler
07/01/20 Jefferies
Amgen win on Enbrel patent removes key overhang, says Jefferies
07/01/20 Goldman Sachs
Global Blood Therapeutics upgraded to Buy from Neutral at Goldman Sachs
SNY Sanofi
$52.43 /

-0.1 (-0.19%)

07/31/20 JPMorgan
Sanofi price target raised to EUR 106 from EUR 103 at JPMorgan
07/20/20 BMO Capital
Immunic initiated with an Outperform at BMO Capital
07/08/20 Piper Sandler
Piper upgrades Kiadis on 'platform validating' Sanofi deal
07/06/20 Citi
BioMarin price target raised to $148 from $105 at Citi
MRNA Moderna
$74.10 /

-3.5 (-4.51%)

07/27/20 Piper Sandler
Piper reiterates $134 Moderna target on start of Phase III vaccine trial
07/27/20 BMO Capital
Moderna price target lowered to $94 from $112 at BMO Capital
07/24/20 Baird
Arbutus Biopharma upside priced in, Baird downgrades to Neutral
SNAP Snap
$22.41 /

+ (+0.00%)

07/28/20 Morgan Stanley
Morgan Stanley lowers near-term, long-term forecasts for Roku
07/22/20
Fly Intel: Top five analyst downgrades
07/22/20 Oppenheimer
Snap price target raised to $28 from $18 at Oppenheimer
07/22/20 JPMorgan
Snap should be bought on any meaningful pullback, says JPMorgan
TWTR Twitter
$36.39 /

-0.34 (-0.93%)

07/24/20 Truist
Twitter price target raised to $40 from $32 at SunTrust
07/24/20 Argus
Twitter price target raised to $46 from $40 at Argus
07/24/20 Canaccord
Twitter price target raised to $40 from $32 at Canaccord
FB Facebook
$253.82 /

+19.19 (+8.18%)

07/31/20
Facebook price target raised to $300 from $290 at JPMorgan
07/31/20 Wedbush
Facebook price target raised to $300 from $250 at Wedbush
07/31/20 RBC Capital
Facebook price target raised to $320 from $271 at RBC Capital
07/31/20 Raymond James
Facebook price target raised to $280 from $240 at Raymond James
GOOG Alphabet
$1,482.46 /

-52.125 (-3.40%)

07/31/20
Fly Intel: Top five analyst downgrades
07/31/20 Guggenheim
Alphabet price target raised to $1,725 from $1,580 at Guggenheim
07/31/20 Raymond James
Alphabet price target raised to $1,700 from $1,425 at Raymond James
07/31/20 Oppenheimer
Alphabet price target raised to $1,685 from $1,445 at Oppenheimer
GOOGL Alphabet Class A
$1,487.69 /

-48.81 (-3.18%)

07/31/20 RBC Capital
Alphabet price target raised to $1,700 from $1,500 at RBC Capital
07/31/20 Morgan Stanley
Alphabet price target raised to $1,760 from $1,700 at Morgan Stanley
07/31/20 Barclays
Alphabet price target raised to $1,800 from $1,600 at Barclays
AMZN Amazon.com
$3,165.00 /

+114.03 (+3.74%)

07/31/20 BMO Capital
Amazon.com price target raised to $3,700 from $3,500 at BMO Capital
07/31/20 RBC Capital
Amazon.com price target raised to $3,800 from $3,300 at RBC Capital
07/31/20 Guggenheim
Amazon.com price target raised to $3,600 from $2,700 at Guggenheim
07/31/20 Goldman Sachs
Amazon.com price target raised to $4,200 from $3,800 at Goldman Sachs
AAPL Apple
$425.02 /

+39.88 (+10.35%)

07/31/20 Canaccord
Canaccord boosts Apple target to $460 after 'impressive' quarter
07/31/20 RBC Capital
Apple price target raised to $445 from $390 at RBC Capital
07/31/20
Apple price target raised to $460 from $425 at JPMorgan
07/31/20 Loop Capital
Apple price target raised to $376 from $330 at Loop Capital
KODK Eastman Kodak
$22.30 /

-7.53 (-25.24%)

RHHBY Roche
$0.00 /

+ (+0.00%)

07/29/20 UBS
Roche price target raised to CHF 390 from CHF 380 at UBS
07/29/20 Morgan Stanley
Roche price target raised to CHF 375 from CHF 370 at Morgan Stanley
07/24/20 Credit Suisse
Credit Suisse backs Neutral on Roche after H1 results
07/24/20 UBS
Roche Q2 sales weak but recovery in June is evident, says UBS
TWTR Twitter
$36.39 /

-0.34 (-0.93%)

SNY Sanofi
$52.43 /

-0.1 (-0.19%)

SNAP Snap
$22.41 /

+ (+0.00%)

RHHBY Roche
$0.00 /

+ (+0.00%)

PFE Pfizer
$38.48 /

-0.27 (-0.70%)

NVS Novartis
$82.09 /

-2.115 (-2.51%)

MSFT Microsoft
$205.00 /

+1.135 (+0.56%)

MRNA Moderna
$74.10 /

-3.5 (-4.51%)

MRK Merck
$80.26 /

+1.21 (+1.53%)

LLY Eli Lilly
$150.24 /

-2.71 (-1.77%)

JNJ Johnson & Johnson
$145.78 /

-1.09 (-0.74%)

GSK GlaxoSmithKline
$40.31 /

+0.045 (+0.11%)

GOOG Alphabet
$1,482.46 /

-52.125 (-3.40%)

FB Facebook
$253.82 /

+19.19 (+8.18%)

BMY Bristol-Myers
$58.66 /

-0.22 (-0.37%)

AZN AstraZeneca
$55.77 /

-2.13 (-3.68%)

AMZN Amazon.com
$3,165.00 /

+114.03 (+3.74%)

AAPL Apple
$425.02 /

+39.88 (+10.35%)

  • 19
    May
  • 12
    Feb
TWTR Twitter
$36.39 /

-0.34 (-0.93%)

SNY Sanofi
$52.43 /

-0.1 (-0.19%)

SNAP Snap
$22.41 /

+ (+0.00%)

RHHBY Roche
$0.00 /

+ (+0.00%)

PFE Pfizer
$38.48 /

-0.27 (-0.70%)

NVS Novartis
$82.09 /

-2.115 (-2.51%)

MSFT Microsoft
$205.00 /

+1.135 (+0.56%)

MRNA Moderna
$74.10 /

-3.5 (-4.51%)

MRK Merck
$80.26 /

+1.21 (+1.53%)

LLY Eli Lilly
$150.24 /

-2.71 (-1.77%)

KODK Eastman Kodak
$22.30 /

-7.53 (-25.24%)

JNJ Johnson & Johnson
$145.78 /

-1.09 (-0.74%)

GSK GlaxoSmithKline
$40.31 /

+0.045 (+0.11%)

GOOG Alphabet
$1,482.46 /

-52.125 (-3.40%)

BMY Bristol-Myers
$58.66 /

-0.22 (-0.37%)

AZN AstraZeneca
$55.77 /

-2.13 (-3.68%)

AMZN Amazon.com
$3,165.00 /

+114.03 (+3.74%)

AAPL Apple
$425.02 /

+39.88 (+10.35%)

TWTR Twitter
$36.39 /

-0.34 (-0.93%)

SNY Sanofi
$52.43 /

-0.1 (-0.19%)

SNAP Snap
$22.41 /

+ (+0.00%)

RHHBY Roche
$0.00 /

+ (+0.00%)

PFE Pfizer
$38.48 /

-0.27 (-0.70%)

NVS Novartis
$82.09 /

-2.115 (-2.51%)

MSFT Microsoft
$205.00 /

+1.135 (+0.56%)

MRNA Moderna
$74.10 /

-3.5 (-4.51%)

MRK Merck
$80.26 /

+1.21 (+1.53%)

LLY Eli Lilly
$150.24 /

-2.71 (-1.77%)

GSK GlaxoSmithKline
$40.31 /

+0.045 (+0.11%)

GOOGL Alphabet Class A
$1,487.69 /

-48.81 (-3.18%)

FB Facebook
$253.82 /

+19.19 (+8.18%)

BMY Bristol-Myers
$58.66 /

-0.22 (-0.37%)

AZN AstraZeneca
$55.77 /

-2.13 (-3.68%)

TWTR Twitter
$36.39 /

-0.34 (-0.93%)

SNY Sanofi
$52.43 /

-0.1 (-0.19%)

SNAP Snap
$22.41 /

+ (+0.00%)

PFE Pfizer
$38.48 /

-0.27 (-0.70%)

NVS Novartis
$82.09 /

-2.115 (-2.51%)

MSFT Microsoft
$205.00 /

+1.135 (+0.56%)

MRNA Moderna
$74.10 /

-3.5 (-4.51%)

MRK Merck
$80.26 /

+1.21 (+1.53%)

LLY Eli Lilly
$150.24 /

-2.71 (-1.77%)

KODK Eastman Kodak
$22.30 /

-7.53 (-25.24%)

JNJ Johnson & Johnson
$145.78 /

-1.09 (-0.74%)

GSK GlaxoSmithKline
$40.31 /

+0.045 (+0.11%)

GOOGL Alphabet Class A
$1,487.69 /

-48.81 (-3.18%)

GOOG Alphabet
$1,482.46 /

-52.125 (-3.40%)

FB Facebook
$253.82 /

+19.19 (+8.18%)

BMY Bristol-Myers
$58.66 /

-0.22 (-0.37%)

AZN AstraZeneca
$55.77 /

-2.13 (-3.68%)

AMZN Amazon.com
$3,165.00 /

+114.03 (+3.74%)

AAPL Apple
$425.02 /

+39.88 (+10.35%)

MSFT Microsoft
$205.00 /

+1.135 (+0.56%)

GOOG Alphabet
$1,482.46 /

-52.125 (-3.40%)

AMZN Amazon.com
$3,165.00 /

+114.03 (+3.74%)

Friday
Recommendations
Barclays backs Underweight on GSK after 'challenging' Q2 » 14:46
07/31/20
07/31
14:46
07/31/20
14:46
GSK

GlaxoSmithKline

$40.10 /

-0.16 (-0.40%)

Barclays analyst Emmanuel…

Barclays analyst Emmanuel Papadakis reiterated an Underweight rating and GBp 1,550 price target on GlaxoSmithKline after a "challenging" Q2 report from the company. Papadakis said that the results proved "something of a return to the earth" following the Q1 pandemic-stocking-related reprieve, providing "limited grounds" for operational enthusiasm short term.

ShowHide Related Items >><<
GSK GlaxoSmithKline
$40.10 /

-0.16 (-0.40%)

GSK GlaxoSmithKline
$40.10 /

-0.16 (-0.40%)

07/30/20 Roth Capital
Roth Capital bullish on Ideaya as GSK highlights synthetic lethality pipeline
07/13/20 UBS
UBS reiterates Buy on GSK as FDA belantamab docs are out
07/13/20 JPMorgan
Ideaya upgraded to Overweight on recent pullback at JPMorgan
06/23/20 Maxim
Inovio price target raised to $24 from $18 at Maxim
GSK GlaxoSmithKline
$40.10 /

-0.16 (-0.40%)

GSK GlaxoSmithKline
$40.10 /

-0.16 (-0.40%)

GSK GlaxoSmithKline
$40.10 /

-0.16 (-0.40%)

GSK GlaxoSmithKline
$40.10 /

-0.16 (-0.40%)

Recommendations
Sanofi price target raised to EUR 106 from EUR 103 at JPMorgan » 14:28
07/31/20
07/31
14:28
07/31/20
14:28
SNY

Sanofi

$51.91 /

-0.625 (-1.19%)

JPMorgan analyst Richard…

JPMorgan analyst Richard Vosser raised the firm's price target on Sanofi to EUR 106 from EUR 103 and keeps an Overweight rating on the shares.

ShowHide Related Items >><<
SNY Sanofi
$51.91 /

-0.625 (-1.19%)

SNY Sanofi
$51.91 /

-0.625 (-1.19%)

07/20/20 BMO Capital
Immunic initiated with an Outperform at BMO Capital
07/08/20 Piper Sandler
Piper upgrades Kiadis on 'platform validating' Sanofi deal
07/06/20 Citi
BioMarin price target raised to $148 from $105 at Citi
07/01/20 Roth Capital
Applied Genetic may attract Sanofi takeover interest, says Roth Capital
SNY Sanofi
$51.91 /

-0.625 (-1.19%)

SNY Sanofi
$51.91 /

-0.625 (-1.19%)

SNY Sanofi
$51.91 /

-0.625 (-1.19%)

SNY Sanofi
$51.91 /

-0.625 (-1.19%)

Options
Unusually active option classes on open July 31st » 09:40
07/31/20
07/31
09:40
07/31/20
09:40
GSK

GlaxoSmithKline

$40.26 /

+ (+0.00%)

, UA

Under Armour

$10.20 /

+ (+0.00%)

, FXI

iShares China Large-Cap ETF

$41.82 /

+0.04 (+0.10%)

, NOK

Nokia

$4.44 /

+ (+0.00%)

, VOD

Vodafone

$15.67 /

+ (+0.00%)

, PINS

Pinterest

$25.15 /

+ (+0.00%)

, CAT

Caterpillar

$136.63 /

+ (+0.00%)

, QCOM

Qualcomm

$107.17 /

+ (+0.00%)

, MRK

Merck

$79.05 /

+ (+0.00%)

, CVX

Chevron

$86.29 /

+ (+0.00%)

Unusual total active…

Unusual total active option classes on open include: GlaxoSmithKline (GSK), Under Armour (UA), iShares China Large Cap ETF (FXI), Nokia (NOK), Vodafone (VOD), Pinterest (PINS), Caterpillar (CAT), Qualcomm (QCOM), Merck (MRK), and Chevron (CVX).

ShowHide Related Items >><<
VOD Vodafone
$15.67 /

+ (+0.00%)

UA Under Armour
$10.20 /

+ (+0.00%)

QCOM Qualcomm
$107.17 /

+ (+0.00%)

PINS Pinterest
$25.15 /

+ (+0.00%)

NOK Nokia
$4.44 /

+ (+0.00%)

MRK Merck
$79.05 /

+ (+0.00%)

GSK GlaxoSmithKline
$40.26 /

+ (+0.00%)

CVX Chevron
$86.29 /

+ (+0.00%)

CAT Caterpillar
$136.63 /

+ (+0.00%)

GSK GlaxoSmithKline
$40.26 /

+ (+0.00%)

07/30/20 Roth Capital
Roth Capital bullish on Ideaya as GSK highlights synthetic lethality pipeline
07/13/20 UBS
UBS reiterates Buy on GSK as FDA belantamab docs are out
07/13/20 JPMorgan
Ideaya upgraded to Overweight on recent pullback at JPMorgan
06/23/20 Maxim
Inovio price target raised to $24 from $18 at Maxim
UA Under Armour
$10.20 /

+ (+0.00%)

07/28/20 Jefferies
Under Armour 'inquiry matters, but it doesn't matter,' says Jefferies
07/23/20 Jefferies
Jefferies 'wouldn't chase' Nike shares near all-time highs
07/10/20 Morgan Stanley
Under Armour appears to be taking 'prudent look' at costs, says Morgan Stanley
05/12/20 Barclays
Under Armour price target lowered to $9 from $10 at Barclays
FXI iShares China Large-Cap ETF
$41.82 /

+0.04 (+0.10%)

NOK Nokia
$4.44 /

+ (+0.00%)

07/28/20 Raymond James
Corning results provide read-through to optical names, says Raymond James
07/14/20 Northland
Nokia product launches underscore breadth of technology, says Northland
07/08/20 JPMorgan
Nokia downgraded to Neutral from Overweight at JPMorgan
07/06/20 Rosenblatt
Samsung on track to replace Nokia as 5G RAN supplier at Verizon, says Rosenblatt
VOD Vodafone
$15.67 /

+ (+0.00%)

07/24/20 Deutsche Bank
Vodafone named new short-term Buy catalyst call idea at Deutsche Bank
07/24/20 Deutsche Bank
Vodafone named new short-term Buy catalyst call idea at Deutsche Bank
07/09/20 Deutsche Bank
Vodafone price target raised to 225 GBp from 220 GBp at Deutsche Bank
07/07/20 JPMorgan
Vodafone price target raised to 190 GBp from 180 GBp at JPMorgan
PINS Pinterest
$25.15 /

+ (+0.00%)

07/21/20 Deutsche Bank
Pinterest price target raised to $29 from $27 at Deutsche Bank
07/20/20 Goldman Sachs
Pinterest price target raised to $26 from $17 at Goldman Sachs
07/15/20 JPMorgan
Pinterest price target raised to $26 from $17 at JPMorgan
07/13/20 Barclays
Pinterest price target raised to $26 from $20 at Barclays
CAT Caterpillar
$136.63 /

+ (+0.00%)

07/24/20 Stifel
Caterpillar price target raised to $150 from $135 at Stifel
07/08/20
Fly Intel: Top five analyst upgrades
07/08/20 BofA
Herc Holdings upgraded to Buy, Caterpillar upgraded to Neutral at BofA
07/08/20 BofA
Caterpillar upgraded to Neutral from Underperform at BofA
QCOM Qualcomm
$107.17 /

+ (+0.00%)

07/31/20 Edward Jones
Qualcomm upgraded to Hold on Huawei settlement at Edward Jones
07/31/20 Edward Jones
Qualcomm upgraded to Hold from Sell at Edward Jones
07/30/20 RBC Capital
Qualcomm price target raised to $106 from $81 at RBC Capital
07/30/20 Wells Fargo
Qualcomm price target raised to $90 from $70 at Wells Fargo
MRK Merck
$79.05 /

+ (+0.00%)

07/30/20 BofA
BofA says hard to compare Moderna COVID data to competing preclinical data
07/27/20 H.C. Wainwright
Agreement termination 'optimal' for Vyleesi future, says H.C. Wainwright
06/30/20 SVB Leerink
Seattle Genetics price target raised to $167 from $155 at SVB Leerink
06/30/20 Oppenheimer
Seattle Genetics price target raised to $210 from $200 at Oppenheimer
CVX Chevron
$86.29 /

+ (+0.00%)

07/23/20 Truist
SunTrust starts Chevron with Buy rating, $120 price target
07/23/20 Truist
Chevron initiated with a Buy at SunTrust
07/22/20 Argus
Noble Energy downgraded to Sell from Hold at Argus
07/21/20 Morgan Stanley
Chevron discipline paid off with deal for Noble, says Morgan Stanley
UA Under Armour
$10.20 /

+ (+0.00%)

QCOM Qualcomm
$107.17 /

+ (+0.00%)

PINS Pinterest
$25.15 /

+ (+0.00%)

NOK Nokia
$4.44 /

+ (+0.00%)

MRK Merck
$79.05 /

+ (+0.00%)

GSK GlaxoSmithKline
$40.26 /

+ (+0.00%)

CVX Chevron
$86.29 /

+ (+0.00%)

CAT Caterpillar
$136.63 /

+ (+0.00%)

  • 16
    Oct
VOD Vodafone
$15.67 /

+ (+0.00%)

UA Under Armour
$10.20 /

+ (+0.00%)

QCOM Qualcomm
$107.17 /

+ (+0.00%)

PINS Pinterest
$25.15 /

+ (+0.00%)

NOK Nokia
$4.44 /

+ (+0.00%)

MRK Merck
$79.05 /

+ (+0.00%)

GSK GlaxoSmithKline
$40.26 /

+ (+0.00%)

CVX Chevron
$86.29 /

+ (+0.00%)

CAT Caterpillar
$136.63 /

+ (+0.00%)

UA Under Armour
$10.20 /

+ (+0.00%)

QCOM Qualcomm
$107.17 /

+ (+0.00%)

PINS Pinterest
$25.15 /

+ (+0.00%)

NOK Nokia
$4.44 /

+ (+0.00%)

MRK Merck
$79.05 /

+ (+0.00%)

GSK GlaxoSmithKline
$40.26 /

+ (+0.00%)

CVX Chevron
$86.29 /

+ (+0.00%)

CAT Caterpillar
$136.63 /

+ (+0.00%)

VOD Vodafone
$15.67 /

+ (+0.00%)

UA Under Armour
$10.20 /

+ (+0.00%)

QCOM Qualcomm
$107.17 /

+ (+0.00%)

PINS Pinterest
$25.15 /

+ (+0.00%)

NOK Nokia
$4.44 /

+ (+0.00%)

MRK Merck
$79.05 /

+ (+0.00%)

GSK GlaxoSmithKline
$40.26 /

+ (+0.00%)

FXI iShares China Large-Cap ETF
$41.82 /

+0.04 (+0.10%)

CVX Chevron
$86.29 /

+ (+0.00%)

CAT Caterpillar
$136.63 /

+ (+0.00%)

FXI iShares China Large-Cap ETF
$41.82 /

+0.04 (+0.10%)

Hot Stocks
Sanofi, GSK selected for Operation Warp Speed to supply 100M doses of vaccine » 07:03
07/31/20
07/31
07:03
07/31/20
07:03
SNY

Sanofi

$52.53 /

-0.3 (-0.57%)

, GSK

GlaxoSmithKline

$40.26 /

-0.34 (-0.84%)

Sanofi (SNY) and GSK…

Sanofi (SNY) and GSK (GSK) announce a collaborative effort with the U.S. government to accelerate the development and manufacturing of a COVID-19 recombinant protein-based vaccine. The vaccine candidate, developed by Sanofi in partnership with GSK, is based on the recombinant protein-based technology used by Sanofi to produce an influenza vaccine, and GSK's established pandemic adjuvant technology. Collaborating with the U.S. Department of Health and Human Services and Department of Defense will help fund the development activities and secure scale-up of Sanofi's and GSK's manufacturing capabilities in the United States for the recombinant protein-based, adjuvanted vaccine, resulting in a significant increase in capacity. The U.S. government will provide up to $2.1B, more than half of which is to support further development of the vaccine, including clinical trials, with the remainder used for manufacturing scale-up and delivery of an initial 100 million doses of the vaccine. Sanofi will receive the majority of the U.S. government funding. The U.S. government has a further option for the supply of an additional 500 million doses longer term. This helps the U.S. government's Operation Warp Speed goals of providing millions of doses of a safe and effective COVID-19 vaccine. Sanofi is leading the clinical development and registration of the COVID-19 vaccine and expects a Phase 1/2 study to start in September, followed by a Phase 3 study by the end of 2020. If the data are positive, the companies can request U.S. regulatory approval in the first half of 2021. In parallel, Sanofi and GSK are scaling up manufacturing of the antigen and adjuvant to produce up to one billion doses per year globally.

ShowHide Related Items >><<
SNY Sanofi
$52.53 /

-0.3 (-0.57%)

GSK GlaxoSmithKline
$40.26 /

-0.34 (-0.84%)

SNY Sanofi
$52.53 /

-0.3 (-0.57%)

07/20/20 BMO Capital
Immunic initiated with an Outperform at BMO Capital
07/08/20 Piper Sandler
Piper upgrades Kiadis on 'platform validating' Sanofi deal
07/06/20 Citi
BioMarin price target raised to $148 from $105 at Citi
07/01/20 Roth Capital
Applied Genetic may attract Sanofi takeover interest, says Roth Capital
GSK GlaxoSmithKline
$40.26 /

-0.34 (-0.84%)

07/30/20 Roth Capital
Roth Capital bullish on Ideaya as GSK highlights synthetic lethality pipeline
07/13/20 UBS
UBS reiterates Buy on GSK as FDA belantamab docs are out
07/13/20 JPMorgan
Ideaya upgraded to Overweight on recent pullback at JPMorgan
06/23/20 Maxim
Inovio price target raised to $24 from $18 at Maxim
SNY Sanofi
$52.53 /

-0.3 (-0.57%)

GSK GlaxoSmithKline
$40.26 /

-0.34 (-0.84%)

SNY Sanofi
$52.53 /

-0.3 (-0.57%)

GSK GlaxoSmithKline
$40.26 /

-0.34 (-0.84%)

SNY Sanofi
$52.53 /

-0.3 (-0.57%)

GSK GlaxoSmithKline
$40.26 /

-0.34 (-0.84%)

SNY Sanofi
$52.53 /

-0.3 (-0.57%)

GSK GlaxoSmithKline
$40.26 /

-0.34 (-0.84%)

Hot Stocks
BioNTech announces strategic collaboration with Regeneron » 05:41
07/31/20
07/31
05:41
07/31/20
05:41
BNTX

BioNTech

$84.02 /

+1.6 (+1.94%)

, REGN

Regeneron

$630.81 /

-0.5 (-0.08%)

, SNY

Sanofi

$52.53 /

-0.3 (-0.57%)

BioNTech SE (BNTX)…

BioNTech SE (BNTX) announced a strategic collaboration with Regeneron (REGN) for a clinical trial combining BioNTech's BNT111 FixVac product candidate and Libtayo, a fully human anti-PD-1 therapy, for the treatment of melanoma. BioNTech said in a release, "The companies plan to jointly conduct a randomized Phase 2 study in patients with anti-PD1-refractory/relapsed, unresectable Stage III or IV cutaneous melanoma. Melanoma is the deadliest skin cancer and estimated to kill more than 63,000 people around the world this year. BNT111 is the most advanced of five clinical stage FixVac product candidates within BioNTech's broader development pipeline. It is an mRNA cancer immunotherapy targeting four antigens frequently expressed in the tumors of patients with melanoma - NY-ESO-1, MAGE-A3, tyrosinase, and TPTE. BNT111 has demonstrated clinical anti-tumor activity as a monotherapy and in combination with checkpoint inhibitors in an ongoing Phase 1 trial in patients with advanced melanoma after prior checkpoint blockade. The two companies plan to pursue a clinical trial for the combination in the second-line treatment setting for advanced melanoma. The companies plan to disclose more details related to the planned Phase 2 study in the third quarter of 2020, with the goal of initiating the trial in the fourth quarter of 2020. Under the terms of the agreement, development costs for the clinical trial will be shared equally and both companies will contribute their products for the trial. Each party will retain full commercial rights for its respective product and record revenues related to its own product. Libtayo is being jointly developed by Regeneron and Sanofi (SNY)."

ShowHide Related Items >><<
SNY Sanofi
$52.53 /

-0.3 (-0.57%)

REGN Regeneron
$630.81 /

-0.5 (-0.08%)

BNTX BioNTech
$84.02 /

+1.6 (+1.94%)

BNTX BioNTech
$84.02 /

+1.6 (+1.94%)

07/30/20 BofA
BofA says hard to compare Moderna COVID data to competing preclinical data
07/30/20 Morgan Stanley
Pfizer price target raised to $42 from $36 at Morgan Stanley
07/21/20
Fly Intel: Top five analyst upgrades
07/21/20 Canaccord
BioNTech price target raised to $97 from $75 at Canaccord
REGN Regeneron
$630.81 /

-0.5 (-0.08%)

07/20/20 Credit Suisse
Regeneron price target raised to $716 from $700 at Credit Suisse
07/09/20
Fly Intel: Top five analyst upgrades
07/08/20 Truist
Regeneron upgraded to Buy at SunTrust on Eylea resilience and pipeline
07/08/20 Truist
Regeneron upgraded to Buy from Hold at SunTrust
SNY Sanofi
$52.53 /

-0.3 (-0.57%)

07/20/20 BMO Capital
Immunic initiated with an Outperform at BMO Capital
07/08/20 Piper Sandler
Piper upgrades Kiadis on 'platform validating' Sanofi deal
07/06/20 Citi
BioMarin price target raised to $148 from $105 at Citi
07/01/20 Roth Capital
Applied Genetic may attract Sanofi takeover interest, says Roth Capital
SNY Sanofi
$52.53 /

-0.3 (-0.57%)

REGN Regeneron
$630.81 /

-0.5 (-0.08%)

BNTX BioNTech
$84.02 /

+1.6 (+1.94%)

  • 23
    Jul
  • 27
    May
  • 06
    Feb
  • 10
    Oct
SNY Sanofi
$52.53 /

-0.3 (-0.57%)

REGN Regeneron
$630.81 /

-0.5 (-0.08%)

BNTX BioNTech
$84.02 /

+1.6 (+1.94%)

SNY Sanofi
$52.53 /

-0.3 (-0.57%)

REGN Regeneron
$630.81 /

-0.5 (-0.08%)

BNTX BioNTech
$84.02 /

+1.6 (+1.94%)

SNY Sanofi
$52.53 /

-0.3 (-0.57%)

REGN Regeneron
$630.81 /

-0.5 (-0.08%)

BNTX BioNTech
$84.02 /

+1.6 (+1.94%)

Thursday
Hot Stocks
GlaxoSmithKline awarded $342M Army contract to procure COVID-19 vaccines » 17:34
07/30/20
07/30
17:34
07/30/20
17:34
GSK

GlaxoSmithKline

$40.26 /

-0.34 (-0.84%)

GlaxoSmithKline was…

GlaxoSmithKline was awarded a $342M firm-fixed-price contract to procure mass quantities of COVID-19 vaccines from multiple vendors to support military locations and personnel throughout the continental U.S. and outside the continental U.S. Bids were solicited via the internet with one received. Work will be performed in Research Triangle Park, North Carolina, with an estimated completion date of February 28, 2021. FY20 research, development, test and evaluation funds in the amount of $342M were obligated at the time of the award. U.S. Army Contracting Command is the contracting activity.

ShowHide Related Items >><<
GSK GlaxoSmithKline
$40.26 /

-0.34 (-0.84%)

GSK GlaxoSmithKline
$40.26 /

-0.34 (-0.84%)

07/30/20 Roth Capital
Roth Capital bullish on Ideaya as GSK highlights synthetic lethality pipeline
07/13/20 UBS
UBS reiterates Buy on GSK as FDA belantamab docs are out
07/13/20 JPMorgan
Ideaya upgraded to Overweight on recent pullback at JPMorgan
06/23/20 Maxim
Inovio price target raised to $24 from $18 at Maxim
GSK GlaxoSmithKline
$40.26 /

-0.34 (-0.84%)

GSK GlaxoSmithKline
$40.26 /

-0.34 (-0.84%)

GSK GlaxoSmithKline
$40.26 /

-0.34 (-0.84%)

GSK GlaxoSmithKline
$40.26 /

-0.34 (-0.84%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.